Table 1.

Clinical and molecular characteristics according to three epigenotypes

Clinical or molecular featuresAll casesHMEIMELMEOutlierP (3 epigenotypes)P (IME vs LME)
Total sample number149 (100%)17 (11%)60 (40%)54 (36%)18 (12%)
Gender
    Male85 (57%)5 (29%)35 (58%)35 (65%)10 (56%)0.038*0.56
    Female64 (43%)12 (71%)25 (42%)19 (35%)8 (44%)
Age, y
    Mean ± SD62.8 ± 9.469.0 ± 8.960.9 ± 9.262.1 ± 9.665.2 ± 6.88.5 × 10−3*0.51
Tumor location
    Proximal54 (36%)15 (88%)20 (33%)10 (19%)9 (50%)8.7 × 10−7*0.090
    Distal95 (64%)2 (12%)40 (67%)44 (81%)9 (50%)
Mucinous component
    (+)27 (18%)9 (53%)16 (24%)0 (0%)2 (11%)9.7 × 10−8*1.4 × 10−5
    (−)122 (82%)8 (47%)44 (76%)54 (100%)16 (89%)
Poorly diff. component
    (+)20 (13%)6 (35%)9 (15%)3 (6%)2 (11%)7.5 × 10−3*0.13
    (−)129 (87%)11 (65%)51 (85%)51 (94%)16 (89%)
AJCC Stage
    I2 (1%)2 (12%)0 (0%)0 (0%)0 (0%)0.0530.29
    II42 (28%)6 (35%)19 (32%)11 (20%)6 (33%)
    III50 (34%)6 (35%)19 (32%)24 (44%)1 (6%)
    IV55 (17%)3 (18%)22 (37%)19 (35%)11 (61%)
Lymph node metastasis
    (+)90 (60%)9 (53%)36 (60%)38 (70%)7 (39%)0.270.23
    (−)58 (39%)8 (47%)24 (40%)15 (28%)11 (61%)
    Unknown1 (1%)0 (0%)0 (0%)1 (2%)0 (0%)
Lymph vessel invasion
    (+)117 (79%)15 (88%)48 (80%)40 (74%)14 (78%)0.480.51
    (−)32 (21%)2 (12%)12 (20%)14 (26%)4 (22%)
Venous invasion
    (+)122 (82%)12 (71%)49 (81%)45 (83%)16 (89%)0.481
    (−)27 (18%)5 (29%)11 (19%)9 (17%)2 (11%)
Microsatellite
    MSI-H17 (11%)13 (76%)2 (3%)0 (0%)2 (11%)4.0 × 10−13*0.50
    MSS132 (89%)4 (24%)58 (97%)54 (100%)16 (89%)
BRAF mutation
    (+)13 (9%)12 (72%)0 (0%)0 (0%)1 (6%)2.0 × 10−13*1
    (−)136 (91%)5 (28%)60 (100%)54 (100%)17 (94%)
KRAS mutation
    (+)60 (40%)3 (18%)38 (63%)14 (26%)5 (28%)2.3 × 10−5*7.4 × 10−5
    (−)89 (60%)14 (82%)22 (37%)40 (74%)13 (72%)
p53-IHC
    (+)70 (47%)0 (0%)29 (48%)30 (56%)11 (61%)2.4 × 10−5*0.50
    (−)75 (50%)17 (100%)29 (48%)22 (41%)7 (39%)
    Unknown4 (3%)0 (0%)2 (3%)2 (3%)0 (0%)

NOTE: The number of samples with each clinical or molecular characteristics is shown. Proximal location, cecum to transverse colon. Distal location, descending colon to rectum. Poorly diff. component, poorly differentiated adenocarcinoma component. Abbreviation: AJCC, American Joint Committee on Cancer.

  • *P value among three epigenotypes < 0.05.

  • P value between IME and LME < 0.05.